ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitoticmediated apoptosis in human prostate cancer cells

PeerJ

Volumn 2013, Issue 1, 2013, Pages

  Parrondo, Ricardo ^a   de las Pozas, Alicia ^a   Reiner, Teresita ^a   Perez Stable, Carlos ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

ABT 737; Antimitotic; Apoptosis; Bcl 2 family; Cyclin B1 Cdk1

Indexed keywords

2 METHOXYESTRA 1, 3, 5 (10), 16 TETRAENE 3 CARBOXAMIDE; 2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL) PROPYLAMINO] 3 NITROBENZENESULFONYL] BENZAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALLOGRAFT INFLAMMATORY FACTOR 1; CASPASE INHIBITOR; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C; DOCETAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PURVALANOL A; Q VD; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; WESTERN BLOTTING;

EID: 84885094823     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.144     Document Type: Article

References (58)

1. Allan LA, Clarke PR. 2007. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Molecular Cell 26:301-310 DOI 10.1016/j.molcel.2007.03.019.
2. Andersen JL, Johnson CE, Freel CD, Parrish AB, Day JL, Buchakjian MR, Nutt LK, Thompson JW,Moseley MA, Kornbluth S. 2009. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO Journal 28:3216-3227 DOI 10.1038/emboj.2009.253.
3. Attar RM, Takimoto CH, Gottardis MM. 2009. Castration-resistant prostate cancer: locking up the molecular escape routes. Clinical Cancer Research 15:3251-3255 DOI 10.1158/1078-0432.CCR-08-1171.
4. Basu A, Haldar S. 2003. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Letters 538:41-47 DOI 10.1016/S0014-5793(03)00131-5.
5. Berndtsson M, Konishi Y, Bonni A, Hagg M, Shoshan M, Linder S, Havelka AM. 2005. Phosphorylation of BAD at Ser-128 during mitosis and paclitaxel-induced apoptosis. FEBS Letters 579:3090-3094 DOI 10.1016/j.febslet.2005.04.067.
6. Bray K, Chen HY, Karp CM,May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS,White E. 2009. Bcl-2 modulation to activate apoptosis in prostate cancer. Molecular Cancer Research 7:1487-1496 DOI 10.1158/1541-7786.MCR-09-0166.
7. Castedo M, Perfettini JL, Roumier T, Andreau K,Medema R, Kroemer G. 2004. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23:2825-2837 DOI 10.1038/sj.onc.1207528.
8. Chen S, Dai Y, Harada H, Dent P, Grant S. 2007. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Research 67:782-791 DOI 10.1158/0008-5472.CAN-06-3964.
9. Chipuk JE,Moldoveanu T, Llambi F, Parsons MJ, Green DR. 2010. The BCL-2 family reunion. Molecular Cell 37:299-310 DOI 10.1016/j.molcel.2010.01.025.
10. de Bono JS, Oudard S, Ozguroglu M, Hansen S,Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators. 2010. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154 DOI 10.1016/S0140-6736(10)61389-X.
11. Del GaizoMoore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. 2008. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111:2300-2309 DOI 10.1182/blood-2007-06-098012.
12. Gascoigne KE, Taylor SS. 2008. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14:111-122 DOI 10.1016/j.ccr.2008.07.002.
13. Gomez LA, de las Pozas A, Perez-Stable C. 2006. Sequential combination of flavopiridol and docetaxel reduces the levels of XIAP and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Molecular Cancer Therapeutics 5:1216-1226 DOI 10.1158/1535-7163.MCT-05-0467.
14. Gottlieb RA, Granville DJ. 2002. Analyzing mitochondrial changes during apoptosis. Methods 26:341-347 DOI 10.1016/S1046-2023(02)00040-3.
15. Gray NS,Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH,Morgan DO, Barnes G, LeClerc S,Meijer L, Kim SH, Lockhart DJ, Schultz PG. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538 DOI 10.1126/science.281.5376.533.
16. Hadaschik BA, Gleave ME. 2007. Therapeutic options for hormone-refractory prostate cancer in 2007. Urologic Oncology 25:413-419 DOI 10.1016/j.urolonc.2007.05.010.
17. Haldar S, Basu A, Croce CM. 1998. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Research 58:1609-1615.
18. Haldar S, Jena N, Croce CM. 1995. Inactivation of Bcl-2 by phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 92:4507-4511 DOI 10.1073/pnas.92.10.4507.
19. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I,Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL,Watkins DN, Rudin CM. 2008. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Research 68:2321-2328 DOI 10.1158/0008-5472.CAN-07-5031.
20. Harley ME, Allan LA, Sanderson HS, Clarke PR. 2010. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO Journal 29:2407-2420 DOI 10.1038/emboj.2010.112.
21. Hauck P, Chao BH, Litz J, Krystal GW. 2009. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.Molecular Cancer Therapeutics 8:883-892 DOI 10.1158/1535-7163.MCT-08-1118.
22. Jordan MA,Wilson L. 2004. Microtubules as a target for anticancer drugs. Nature Reviews Cancer 4:253-265 DOI 10.1038/nrc1317.
23. Kang MH, Kang YH, Szymanska B,Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP. 2007. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:2057-2066 DOI 10.1182/blood-2007-03-080325.
24. Karnak D, Xu L. 2010. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Current Drug Targets 11:699-707 DOI 10.2174/138945010791170888.
25. Khor LY,Moughan J, Al-SaleemT, Hammond EH, Venkatesan V, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Pollack A. 2007. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clinical Cancer Research 13:3585-3590 DOI 10.1158/1078-0432.CCR-06-2972.
26. Konishi Y, Lehtinen M, Donovan N, Bonni A. 2002. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Molecular Cell 9:1005-1016 DOI 10.1016/S1097- 2765(02)00524-5.
27. LaCasse EC,Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. 2008. IAP-targeted therapies for cancer. Oncogene 27:6252-6275 DOI 10.1038/onc.2008.302.
28. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM. 2008. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.Molecular Cancer Therapeutics 7:1472-1482 DOI 10.1158/1535-7163.MCT-08-0107.
29. Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, Pawel BR, Hogarty MD. 2009. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biology & Therapy 8:1587-1595 DOI 10.4161/cbt.8.16.8964.
30. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, Roberts AW. 2009. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23:2034-2041 DOI 10.1038/leu.2009.151.
31. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A,Wall NR, Lilly MB, De Leon M, Casiano CA. 2009. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer 8:1-15 DOI 10.1186/1476-4598-8-68.
32. Miyake H,Monia BP, Gleave ME. 2000. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. International Journal of Cancer 86:855-862 DOI 10.1002/(SICI)1097-0215(20000615)86:6<855::AID-IJC15>3.0.CO;2-8.
33. Nantajit D, Fan M, Duru N,Wen Y, Reed JC, Li JJ. 2010. Cyclin B1/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. PLoS ONE 5:e12341 DOI 10.1371/journal.pone.0012341.
34. Nechushtan A, Smith CL, Hsu YT, Youle RJ. 1999. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO Journal 18:2330-2341 DOI 10.1093/emboj/18.9.2330.
35. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E,Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ. 2012. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America 109:2766-2771 DOI 10.1073/pnas.1104778108.
36. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S,Marchisio PC, Altieri DC. 2000. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the National Academy of Sciences of the United States of America 97:13103-13107 DOI 10.1073/pnas.240390697.
37. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C,Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ,Wang B,Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681 DOI 10.1038/nature03579.
38. Perez-Stable C. 2006. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Letters 231:49-64 DOI 10.1016/j.canlet.2005.01.018.
39. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC,Meistrich ML,McDonnell T. 2003. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 97:1630-1638 DOI 10.1002/cncr.11230.
40. Poruchynsky MS,Wang EE, Rudin CM, Blagosklonny MV, Fojo T. 1998. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Research 58:3331-3338.
41. Reiner T, de las Pozas A, Gomez LA, Perez-Stable C. 2009. Low dose combination of 2-methoxyestradiol and docetaxel can block prostate cancer cells in mitosis and induce apoptosis. Cancer Letters 276:21-31 DOI 10.1016/j.canlet.2008.10.026.
42. Shi J, Orth JD,Mitchison T. 2008. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Research 68:3269-3276 DOI 10.1158/0008-5472.CAN-07- 6699.
43. Shi J, Zhou Y, Huang HC,Mitchison TJ. 2011. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Research 71:4518-4526 DOI 10.1158/0008-5472.CAN-10-4336.
44. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK,Marsh K,McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK,Wang B,Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW. 2006. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Research 66:8731-8739 DOI 10.1158/0008-5472.CAN-06-0367.
45. Song JH, Kandasamy K, Kraft AS. 2008. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. Journal of Biological Chemistry 283:25003-25013 DOI 10.1074/jbc.M802511200.
46. Stewart SA, Dykxhoorn DM, Palliser D,Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, HahnWC, Sharp PA,Weinberg RA, Novina CD. 2003. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:493-501 DOI 10.1261/rna.2192803.
47. Susin SA, Lorenzo HK, Zamzami N,Marzo I, Snow BE, Brothers GM,Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. 1999. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441-446 DOI 10.1038/17135.
48. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC,Macher-Goeppinger S, Radlwimmer B,Wiestler OD, Herold-Mende C, Roth W. 2008. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27:6646-6656 DOI 10.1038/onc.2008.259.
49. Tang DG, Li L, Chopra DP, Porter AT. 1998. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Research 58:3466-3479.
50. Tannock IF, deWit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 351:1502-1512 DOI 10.1056/NEJMoa040720.
51. Terrano DT, Upreti M, Chambers TC. 2010. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Molecular and Cellular Biology 30:640-656 DOI 10.1128/MCB.00882-09.
52. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF,Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. 2008. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research 68:3421-3428 DOI 10.1158/0008-5472.CAN-07-5836.
53. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, Chambers TC. 2008. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. Journal of Biological Chemistry 283:35517-35525 DOI 10.1074/jbc.M805019200.
54. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE,Miller HL, Nordeen SK, Miller GJ, Lucia MS. 2003. Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205-225 DOI 10.1002/pros.10290.
55. van Delft MF,Wei AH,Mason KD, Vandenberg CJ, Chen L, Czabotar PE,Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. 2006. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399 DOI 10.1016/j.ccr.2006.08.027.
56. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S, Ludlam MJ, Leong KG, Dueber EC,Maecker H, Huang DC, Dixit VM. 2011. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471:110-114 DOI 10.1038/nature09779.
57. Yecies D, Carlson NE, Deng J, Letai A. 2010. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115:3304-3313 DOI 10.1182/blood-2009-07-233304.
58. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L,MessersmithWA, Treston AM, Eckhardt SG, Sidor C, Camidge DR. 2011. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investigational New Drugs 29:340-346 DOI 10.1007/s10637-009-9383-9.